Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 30, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share transactions executed by the GlaxoSmithKline Employee Trust ("GSK Trust") on behalf of employee plans:
- March 26, 2007: The GSK Trust sold 2,839 Ordinary Shares at GBP 13.99 per share for the GlaxoSmithKline Share Value Plan. Additionally, 15,482 Ordinary Shares were transferred to participants in the same plan.
- March 28, 2007: The GSK Trust transferred 17,505 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
These transactions were advised to the Company on March 29, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust for current and former employees, and three directors (Dr. JP Garnier, Dr. M M Slaoui, and Mr. J S Heslop) hold interests in the trust shares similarly to other employees.
Investor Verification Points
- Verify the total volume of shares sold versus transferred to understand net dilution or buyback activity related to employee plans.
- Confirm the transaction price of GBP 13.99 against the market price on March 26, 2007.
- Review the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting or exercise conditions for the 17,505 shares transferred.